Change in circulating endothelial cells (CEC) and tumor cells (CTC) in patients (pts) receiving bevacizumab and erlotinib for metastatic breast cancer (MBC) predicts stable disease at first evaluation Meeting Abstract

  

Authors:	Rugo, H. S.; Dickler, M. N.; Scott, J. H.; Moore, D. H.; Melisko, M.; Yeh, B. M.; Caravelli, J.; Brogi, E.; Hudis, C.; Park, J. W.
Abstract Title:	Change in circulating endothelial cells (CEC) and tumor cells (CTC) in patients (pts) receiving bevacizumab and erlotinib for metastatic breast cancer (MBC) predicts stable disease at first evaluation
Meeting Title:	41st Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title:	Journal of Clinical Oncology
Volume:	23
Issue:	16 Suppl.
Meeting Dates:	2005 May 13-17
Meeting Location:	Orlando, FL
ISSN:	0732-183X
Publisher:	American Society of Clinical Oncology
Date Published:	2005-06-01
Start Page:	10S
Language:	English
ACCESSION:	WOS:000230326600037
PROVIDER:	wos
DOI:	10.1200/jco.2005.23.16_suppl.525
Notes:	--- - Meeting Abstract: 525 - 41st Annual Meeting of the American-Society-of-Clinical-Oncology - MAY 13-17, 2005 - Orlando, FL - S - Part 1 - "Source: Wos"

https://synapse.mskcc.org/synapse/works/has_related_data_chk/44884